维普中文期刊产品整合服务
20篇 您的检索式:作者名="Barlet H"
    题名 作者 年代 出处 被引量
1lsolation of cells from ovine fetal long bone and characterization of their osteoblastic antivities during in vitro mineralization显示文摘Collignon H Davicco M J Barlet J P 1997Arch Physiol Biochem1997,105,2:1
2Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘Collignon H Davicco MJ Barlet JP 1997Arch Physiol Biochem1997,105,2:1
3Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘Collignon H Davicco MJ Barlet JP 1997Arch Physiol Biochem1997,105,2:1
4lsolation of cells from oxine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘Collignon H Davicco MJ Barlet JP 1997Arch Physiol Biochem1997,105,2:1
5Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘Collignon H Davicco M J Barlet JP 1997Arch Physiol Biochem1997,105,2:1
6Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘Collignon H Davicco M J Barlet J P 1997Arch PhysiolBiochem1997,105,2:1
7FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer显示文摘AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the 'irinotecan-na?ve' patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the 'pre-exposed irinotecan' patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept.CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol Christophe Borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel 2018World Journal of Clinical Oncology2018,9,5:1
8Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization 显示文摘Collignon H Davicco M J Barlet JP 1997Arch Physiol Biochem1997,105,2:1
9Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization 显示文摘Collignon H Davicco M J Barlet J P 1997Arch Physiol Biochem1997,105,2:1
10Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘Colliguon H Davicco MJ Barlet JP 1997Arch Physiol Biochcm1997,105,2:1
11Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘COLLIGNON H DAVICCO M J BARLET J P 1997Arch Physiod Biochem1997,105,:1
12Recent devdopments on the analysis and optimum design of sheet metal forming parts using a simplified inverse approach 显示文摘Y Q Guo J L Batoz H Naceur S Bouabdallah F Mercier O Barlet 2000Computers and Structures 782000,,:1
13Recent developments on the analysis and optimum design of sheet metal forming parts using a simplified inverse approach 显示文摘Guo Y Q Batoz J L Naceur H Bouabdallah F Mercier F Barlet O 2000Computers and Structures2000,78,:1
14Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘COLLIGNON H DAVICCO M J BARLET J P 1997Arch Physiol Biochem1997,105,2:1
15Isolation of cells from ovine fetal long bone and characterization显示文摘Collignon H Davicco MJ Barlet JP 1997Arch Physiol Biochem1997,105,2:1
16Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization 显示文摘Collignon H Davieco MJ Barlet JP 1997Archives of physiology and bio- chemistry1997,105,2:1
17Mechanism of propofol bradycardia 显示文摘Colson P Barlet H Roquefeuill B 1988Anesth Analg1988,67,9:1
18Isolation of cells from bovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘Collignon H Davicco MJ Barlet JP 1997Arch Physiol Biochem1997,105,2:1
19Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization 显示文摘Collignon H Davicco M J Barlet JP 1997Arch Physiol Biochem1997,105,2:1
20Isolation of cellsfrom ovine fetal long bone and characterization of theirosteoblastic activities during in vitro mineralization显示文摘Collignon H Davicco MJ Barlet JP 1997ArchPhysiol Biochem1997,105,2:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费